Relationship between immune ‐related adverse events and treatment effectiveness in extensive disease small cell lung cancer

ConclusionIn this study, the development of irAEs did not affect OS in patients with ED-SCLC who received platinum-based agents, etoposide, or ICI therapy. We determined that managing irAEs and administering first- and second-line therapies could contribute to prolonged OS.

Source: Thoracic Cancer - June 27, 2023 Category: Cancer & Oncology Authors: Keiki Yokoo, Yauo Kitamura, Keito Suzuki, Kohei Morikawa, Takeo Sawai, Hiroyuki Honda, Sayaka Kudo, Gen Yamada Tags: ORIGINAL ARTICLE Source Type: research